Results 351 to 360 of about 191,621 (404)

Efficacy of proton pump inhibitor therapy for eosinophilic oesophagitis in 630 patients: results from the EoE connect registry

Alimentary Pharmacology and Therapeutics, 2020
Proton pump inhibitors (PPIs) are the most commonly used first‐line therapy for patients with eosinophilic oesophagitis (EoE). However, many aspects related to PPIs in EoE are still unknown.
E. Laserna-Mendieta, S. Casabona, D. Guagnozzi, E. Savarino, A. Perelló, A. Guardiola-Arévalo, J. Barrio, I. Pérez-Martínez, Anne Lund Krarup, J. Alcedo, S. de la Riva, Esther Rey-Iborra, C. Santander, Á. Arias, A. Lucendo   +14 more
semanticscholar   +1 more source

Endoscopic treatment of proton pump inhibitor‐refractory gastroesophageal reflux disease with anti‐reflux mucosectomy: Experience of 109 cases

Digestive Endoscopy, 2020
Some patients with gastroesophageal reflux disease (GERD) are refractory to proton pump inhibitor (PPI) therapy. Anti‐reflux mucosectomy (ARMS) is a minimally invasive endoscopic procedure for treatment of GERD.
K. Sumi, H. Inoue, Yasutoshi Kobayashi, Yugo Iwaya, Mary Raina Angeli Abad, Y. Fujiyoshi, Y. Shimamura, H. Ikeda, M. Onimaru   +8 more
semanticscholar   +1 more source

Proton pump inhibitors and osteoporosis

Current Opinion in Rheumatology, 2016
Purpose of review The purpose of the review is to provide an update on recent advances in the evidence based on proton pump inhibitors (PPI) as a possible cause of osteoporosis and osteoporotic fractures. This review focuses, in particular, on new studies published in the last 18 months and a discussion of these findings and ...
Andersen, Bjarne Nesgaard, Johansen, Per Birger, Abrahamsen, Bo   +2 more
openaire   +3 more sources

Pharmacogenomics of proton pump inhibitors

Pharmacogenomics, 2004
Proton pump inhibitors (PPIs), such as omeprazole, lansoprazole, rabeprazole, esomeprazole, and pantoprazole, are metabolized by cytochrome P450 isoenzyme 2C19 (CYP2C19) in the liver. There are genetic differences that affect the activity of this enzyme. The genotypes of CYP2C19 are classified into three groups: homozygous extensive metabolizer (homEM),
Takahisa, Furuta, Naohito, Shirai, Mitsushige, Sugimoto, Kyoichi, Ohashi, Takashi, Ishizaki   +4 more
openaire   +2 more sources

Hypomagnesemia and proton-pump inhibitors

Expert Opinion on Drug Safety, 2013
Proton pump inhibitors (PPIs) have been linked to clinically symptomatic hypomagnesemia.We searched Medline database in all languages using 'proton-pump inhibitors, magnesium, hypomagnesemia and hypomagnesemic hypoparathyroidism' as search terms and other articles were identified through searches of the files of the authors and reference lists from ...
Giuseppe, Famularo, Laura, Gasbarrone, Giovanni, Minisola   +2 more
openaire   +2 more sources

Potential proton pump inhibitor–related adverse effects

Annals of the New York Academy of Sciences, 2020
Proton pump inhibitors (PPIs) are one of the most common medications taken by patients worldwide. PPIs are used to treat acid‐related disorders, including gastroesophageal reflux disease, peptic ulcer disease, Helicobacter pylori infection, and ...
I. E. Perry, I. Sonu, C. Scarpignato, J. Akiyama, M. Hongo, K. Vega   +5 more
semanticscholar   +1 more source

Esomeprazole: a proton pump inhibitor

Expert Review of Gastroenterology & Hepatology, 2009
Proton pump inhibitors (PPIs) are the most potent inhibitors of gastric acid secretion available, and they are effective for treating all acid-related disorders. Esomeprazole is one of several most recent PPIs that became available to the market in 2001.
Ravi, Vachhani, Gregory, Olds, Vic, Velanovich   +2 more
openaire   +2 more sources

Proton Pump Inhibitors for Dyspepsia

Digestive Diseases, 2008
Proton pump inhibitors are widely used in many upper gastrointestinal disorders. Dyspepsia is a common problem in primary care and endoscopy is neither feasible nor affordable in the majority of patients. <i>Helicobacter pylori</i> eradication has been shown to be effective, but with the declining prevalence of <i>H.
openaire   +2 more sources

Reduced risk of gastrointestinal bleeding associated with proton pump inhibitor therapy in patients treated with dual antiplatelet therapy after myocardial infarction.

European Heart Journal, 2019
AIMS Guidelines differ in their recommendations on therapy to prevent gastrointestinal bleeding for patients treated with dual antiplatelet treatment (DAPT).
T. Sehested, N. Carlson, P. Hansen, T. Gerds, M. Charlot, C. Torp-Pedersen, L. Køber, G. Gislason, M. Hlatky, E. Fosbøl   +9 more
semanticscholar   +1 more source

Overuse of proton pump inhibitors

Journal of Clinical Pharmacy and Therapeutics, 2000
There have been concerns raised about the potential adverse effects of proton pump inhibitors, especially with long-term use. In particular, their potent action can suppress the features and delay the diagnosis of gastric cancer, while prolonged exposure may hasten the development of gastric carcinoids.To examine the use of proton pump inhibitors in ...
M, Naunton, G M, Peterson, M D, Bleasel
openaire   +2 more sources